Organ Transplant Immunosuppressant Drugs Market, by Drugs Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR inhibitor (Mammalian Target of Rapamycin), Steroids, and Immunosuppressant Antibodies ), by Therapeutic Organ Transplant Type (Heart Tr

Organ Transplant Immunosuppressant Drugs Market, by Drugs Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR inhibitor (Mammalian Target of Rapamycin), Steroids, and Immunosuppressant Antibodies ), by Therapeutic Organ Transplant Type (Heart Transplant, Kidney Transplant, Liver Transplant, Lung Transplant, Pancreas Transplant, and Others), by Distribution Channel (Hospitals, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

After a successful organ transplant, you may have to take immunosuppressant drugs. These drugs help your immune system from attacking (rejecting) the new organ from which it has been transplanted. In general, they should be taken for your lifetime, or until the treatments are complete. Orally, or injected into a vein, these drugs work by stopping your body's immune cells from further attacking your transplanted organ. They also control your allergic reactions to the transplanted organ and reduce inflammation around the transplanted tissues.
Market Dynamics:
Approval and launch of new drugs is expected to propel growth of the global organ transplant immunosuppressant drugs market over the forecast period. For instance, in July 2021, Kadmon Holdings, Inc. received the U.S. Food and Drug Administration approval for REZUROCK (belumosudil) for the treatment of adult and pediatric patients with chronic graft-versus-host disease.
Negative outcomes in clinical trials is expected to hinder growth of the global organ transplant immunosuppressant drugs market. For instance, in September 2021, Novartis AG announced to halt a mid-stage clinical trial of drug intended to prevent organ rejection after an early look at data in kidney transplant patients showed the experimental treatment was less effective compared to the standard of care therapy.
The market is witnessing several M&A activities. For instance, in September 2021, Sanofi announced to acquire Kadmon Holdings, a U.S.-based biopharmaceutical company.
Key features of the study:
This report provides in-depth analysis of the global organ transplant immunosuppressant drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global organ transplant immunosuppressant drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global organ transplant immunosuppressant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global organ transplant immunosuppressant drugs market
Detailed Segmentation:
Global Organ Transplant Immunosuppressant Drugs Market, By Drug Class:
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitor
Steroids
Antibodies
Global Organ Transplant Immunosuppressant Drugs Market, By Transplant Type:
Kidney
Liver
Heart
Lung
Pancreas
Others
Global Organ Transplant Immunosuppressant Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Organ Transplant Immunosuppressant Drugs Market, By Region:
North America
North America Organ Transplant Immunosuppressant Drugs Market , By Drug Class:
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitor
Steroids
Antibodies
North America Organ Transplant Immunosuppressant Drugs Market , By Transplant Type:
Kidney
Liver
Heart
Lung
Pancreas
Others
North America Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America Organ Transplant Immunosuppressant Drugs Market , By Country:
U.S.
Canada
Latin America
Latin America Organ Transplant Immunosuppressant Drugs Market , By Drug Class:
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitor
Steroids
Antibodies
Latin America Organ Transplant Immunosuppressant Drugs Market , By Transplant Type:
Kidney
Liver
Heart
Lung
Pancreas
Others
Latin America Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America Organ Transplant Immunosuppressant Drugs Market , By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Europe Organ Transplant Immunosuppressant Drugs Market , By Drug Class:
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitor
Steroids
Antibodies
Europe Organ Transplant Immunosuppressant Drugs Market , By Transplant Type:
Kidney
Liver
Heart
Lung
Pancreas
Others
Europe Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe Organ Transplant Immunosuppressant Drugs Market , By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Asia Pacific Organ Transplant Immunosuppressant Drugs Market, By Drug Class:
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitor
Steroids
Antibodies
Asia Pacific Organ Transplant Immunosuppressant Drugs Market , By Transplant Type:
Kidney
Liver
Heart
Lung
Pancreas
Others
Asia Pacific Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific Organ Transplant Immunosuppressant Drugs Market , By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Middle East Organ Transplant Immunosuppressant Drugs Market, By Drug Class:
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitor
Steroids
Antibodies
Middle East Organ Transplant Immunosuppressant Drugs Market, By Transplant Type:
Kidney
Liver
Heart
Lung
Pancreas
Others
Middle East Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East Organ Transplant Immunosuppressant Drugs Market, By Country:
GCC
Israel
Rest of Middle East
Africa
Africa Organ Transplant Immunosuppressant Drugs Market, By Drug Class:
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitor
Steroids
Antibodies
Middle East Organ Transplant Immunosuppressant Drugs Market, By Transplant Type:
Kidney
Liver
Heart
Lung
Pancreas
Others
Middle East Organ Transplant Immunosuppressant Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East Organ Transplant Immunosuppressant Drugs Market, By Country:
North Africa
Central Africa
South Africa
Company Profiles
Astellas Pharma*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategy
Genzyme Corporation
Accord Healthcare Ltd.
Watson Pharmaceuticals, Inc.
Novartis AG
Mylan Laboratories, Inc.
GlaxoSmithKline plc.
Belcher Pharmaceuticals LLC
Leo Pharma AS
Glenmark Pharmaceuticals Ltd.
TFF Pharmaceuticals, Inc.
TolerogenixX GmbH
Veloxis Pharmaceuticals Inc.
Dr. Reddy’s Laboratories Ltd.
Panacea Biotec Ltd.
Strides Pharma Global Pte Ltd.
F-Hoffman La Roche
“*” marked represents similar segmentation in other categories in the respective section.